vs
Alpha Metallurgical Resources, Inc.（AMR）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Alpha Metallurgical Resources, Inc.的1.5倍（$772.1M vs $519.1M），Revvity净利率更高（12.7% vs -3.3%，领先16.1%），Revvity同比增速更快（5.9% vs -15.7%），Revvity自由现金流更多（$161.8M vs $-10.0M），过去两年Revvity的营收复合增速更高（9.0% vs -22.4%）
阿尔法冶金资源（前身为康图拉能源）是行业领先的煤炭供应商，在阿巴拉契亚北部和中部拥有地下及露天煤矿综合体，在宾夕法尼亚州、弗吉尼亚州和西弗吉尼亚州坐拥大型煤田，生产用于炼钢的冶金煤和用于发电的动力煤，供应全球下游客户。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
AMR vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$519.1M
营收增速更快
RVTY
高出21.5%
-15.7%
净利率更高
RVTY
高出16.1%
-3.3%
自由现金流更多
RVTY
多$171.8M
$-10.0M
两年增速更快
RVTY
近两年复合增速
-22.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $519.1M | $772.1M |
| 净利润 | $-17.3M | $98.4M |
| 毛利率 | — | — |
| 营业利润率 | -4.1% | 14.5% |
| 净利率 | -3.3% | 12.7% |
| 营收同比 | -15.7% | 5.9% |
| 净利润同比 | -711.2% | 3.9% |
| 每股收益（稀释后） | $-1.35 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRRVTY
| Q4 25 | $519.1M | $772.1M | ||
| Q3 25 | $525.2M | $698.9M | ||
| Q2 25 | $548.7M | $720.3M | ||
| Q1 25 | $529.7M | $664.8M | ||
| Q4 24 | $615.4M | $729.4M | ||
| Q3 24 | $669.8M | $684.0M | ||
| Q2 24 | $800.1M | $691.7M | ||
| Q1 24 | $861.3M | $649.9M |
净利润AMRRVTY
| Q4 25 | $-17.3M | $98.4M | ||
| Q3 25 | $-5.5M | $46.7M | ||
| Q2 25 | $-5.0M | $53.9M | ||
| Q1 25 | $-33.9M | $42.2M | ||
| Q4 24 | $-2.1M | $94.6M | ||
| Q3 24 | $3.8M | $94.4M | ||
| Q2 24 | $58.9M | $55.4M | ||
| Q1 24 | $127.0M | $26.0M |
毛利率AMRRVTY
| Q4 25 | — | — | ||
| Q3 25 | — | 53.6% | ||
| Q2 25 | — | 54.5% | ||
| Q1 25 | — | 56.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 55.7% | ||
| Q1 24 | — | 54.6% |
营业利润率AMRRVTY
| Q4 25 | -4.1% | 14.5% | ||
| Q3 25 | -0.5% | 11.7% | ||
| Q2 25 | 0.5% | 12.6% | ||
| Q1 25 | -7.6% | 10.9% | ||
| Q4 24 | 1.6% | 16.3% | ||
| Q3 24 | 0.8% | 14.3% | ||
| Q2 24 | 8.8% | 12.4% | ||
| Q1 24 | 16.5% | 6.8% |
净利率AMRRVTY
| Q4 25 | -3.3% | 12.7% | ||
| Q3 25 | -1.1% | 6.7% | ||
| Q2 25 | -0.9% | 7.5% | ||
| Q1 25 | -6.4% | 6.4% | ||
| Q4 24 | -0.3% | 13.0% | ||
| Q3 24 | 0.6% | 13.8% | ||
| Q2 24 | 7.4% | 8.0% | ||
| Q1 24 | 14.7% | 4.0% |
每股收益（稀释后）AMRRVTY
| Q4 25 | $-1.35 | $0.86 | ||
| Q3 25 | $-0.42 | $0.40 | ||
| Q2 25 | $-0.38 | $0.46 | ||
| Q1 25 | $-2.60 | $0.35 | ||
| Q4 24 | $-0.09 | $0.77 | ||
| Q3 24 | $0.29 | $0.77 | ||
| Q2 24 | $4.49 | $0.45 | ||
| Q1 24 | $9.59 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $415.6M | $919.9M |
| 总债务越低越好 | $9.8M | — |
| 股东权益账面价值 | $1.5B | $7.3B |
| 总资产 | $2.3B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.01× | — |
8季度趋势，按日历期对齐
现金及短期投资AMRRVTY
| Q4 25 | $415.6M | $919.9M | ||
| Q3 25 | $457.9M | $931.4M | ||
| Q2 25 | $449.0M | $991.8M | ||
| Q1 25 | $448.0M | $1.1B | ||
| Q4 24 | $481.6M | $1.2B | ||
| Q3 24 | $484.6M | $1.2B | ||
| Q2 24 | $336.1M | $2.0B | ||
| Q1 24 | $269.4M | $1.7B |
总债务AMRRVTY
| Q4 25 | $9.8M | — | ||
| Q3 25 | $2.9M | — | ||
| Q2 25 | $3.1M | — | ||
| Q1 25 | $2.4M | — | ||
| Q4 24 | $2.9M | — | ||
| Q3 24 | $3.6M | — | ||
| Q2 24 | $5.3M | — | ||
| Q1 24 | $6.0M | — |
股东权益AMRRVTY
| Q4 25 | $1.5B | $7.3B | ||
| Q3 25 | $1.6B | $7.4B | ||
| Q2 25 | $1.6B | $7.6B | ||
| Q1 25 | $1.6B | $7.6B | ||
| Q4 24 | $1.6B | $7.7B | ||
| Q3 24 | $1.7B | $7.9B | ||
| Q2 24 | $1.6B | $7.9B | ||
| Q1 24 | $1.6B | $7.8B |
总资产AMRRVTY
| Q4 25 | $2.3B | $12.2B | ||
| Q3 25 | $2.3B | $12.1B | ||
| Q2 25 | $2.4B | $12.4B | ||
| Q1 25 | $2.4B | $12.4B | ||
| Q4 24 | $2.4B | $12.4B | ||
| Q3 24 | $2.5B | $12.8B | ||
| Q2 24 | $2.5B | $13.4B | ||
| Q1 24 | $2.5B | $13.4B |
负债/权益比AMRRVTY
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | — | ||
| Q1 25 | 0.00× | — | ||
| Q4 24 | 0.00× | — | ||
| Q3 24 | 0.00× | — | ||
| Q2 24 | 0.00× | — | ||
| Q1 24 | 0.00× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-10.0M | $161.8M |
| 自由现金流率自由现金流/营收 | -1.9% | 21.0% |
| 资本支出强度资本支出/营收 | 5.6% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $17.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流AMRRVTY
| Q4 25 | $19.0M | $182.0M | ||
| Q3 25 | $50.5M | $138.5M | ||
| Q2 25 | $53.2M | $134.3M | ||
| Q1 25 | $22.2M | $128.2M | ||
| Q4 24 | $56.3M | $174.2M | ||
| Q3 24 | $189.5M | $147.9M | ||
| Q2 24 | $138.1M | $158.6M | ||
| Q1 24 | $196.1M | $147.6M |
自由现金流AMRRVTY
| Q4 25 | $-10.0M | $161.8M | ||
| Q3 25 | $25.4M | $120.0M | ||
| Q2 25 | $18.6M | $115.5M | ||
| Q1 25 | $-16.3M | $112.2M | ||
| Q4 24 | $13.6M | $149.8M | ||
| Q3 24 | $158.0M | $125.6M | ||
| Q2 24 | $77.0M | $136.6M | ||
| Q1 24 | $132.5M | $129.7M |
自由现金流率AMRRVTY
| Q4 25 | -1.9% | 21.0% | ||
| Q3 25 | 4.8% | 17.2% | ||
| Q2 25 | 3.4% | 16.0% | ||
| Q1 25 | -3.1% | 16.9% | ||
| Q4 24 | 2.2% | 20.5% | ||
| Q3 24 | 23.6% | 18.4% | ||
| Q2 24 | 9.6% | 19.7% | ||
| Q1 24 | 15.4% | 20.0% |
资本支出强度AMRRVTY
| Q4 25 | 5.6% | 2.6% | ||
| Q3 25 | 4.8% | 2.6% | ||
| Q2 25 | 6.3% | 2.6% | ||
| Q1 25 | 7.3% | 2.4% | ||
| Q4 24 | 6.9% | 3.4% | ||
| Q3 24 | 4.7% | 3.3% | ||
| Q2 24 | 7.6% | 3.2% | ||
| Q1 24 | 7.4% | 2.7% |
现金转化率AMRRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | 49.81× | 1.57× | ||
| Q2 24 | 2.34× | 2.87× | ||
| Q1 24 | 1.54× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMR
暂无分部数据
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
